2-(4-氯苯基)-4-甲基-1-(4-甲基磺酰基苯基)咪唑 | 177660-54-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(4-氯苯基)-4-甲基-1-(4-甲基磺酰基苯基)咪唑
• 英文名称: 2-(4-chlorophenyl)-4-methyl-1-[4-(methylsulfonyl)phenyl]-1H-imidazole
• 英文别名: 4-methyl-2-(4-chlorophenyl)-1-[(4-methylsulfonyl)phenyl]-1H-imidazole；2-(4-Chlorophenyl)-4-methyl-1-(4-(methylsulfonyl)phenyl)-1H-imidazole；2-(4-chlorophenyl)-4-methyl-1-(4-methylsulfonylphenyl)imidazole
• CAS: 177660-54-7
• 化学式: C₁₇H₁₅ClN₂O₂S
• 分子量: 346.837
• InChiKey: RIZFWOPNUQFLEF-UHFFFAOYSA-N

物化性质

• 熔点：
  60-61 °C
• 沸点：
  569.7±60.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  60.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-甲磺酰基苯胺 在 三甲基铝 、 碳酸氢钠 、 对甲苯磺酸 作用下， 以 异丙醇 为溶剂， 反应 112.5h， 生成 2-(4-氯苯基)-4-甲基-1-(4-甲基磺酰基苯基)咪唑
  参考文献：
  名称：

  1,2-Diarylimidazoles as Potent, Cyclooxygenase-2 Selective, and Orally Active Antiinflammatory Agents

  摘要：

  Series of 1,2-diarylimidazoles has been synthesized and found to contain highly potent and selective inhibitors of the human COX-2 enzyme. The paper describes a short synthesis of the target 1,2-diarylimidazoles starting with aryl nitriles. Different portions of the diarylimidazole (I) were modified to establish SAR. Systematic variations of the substituents in the aryl ring B have yielded very potent (IC50 = 10-100 nm) and selective (1000-12500) inhibitors of the COX-2 enzyme. The study on the influence of substituents in the imidazole ring established that a CF3 group at position 4 gives the optimum oral activity. A number of the diarylimidazoles showed excellent inhibition in the adjuvant induced arthritis model (e.g., ED50 = 0.02 mph for 22 and 34). The diarylimidazoles are also potent inhibitors of carrageenan-induced edema (ED50 = 9-30 mph) sind hyperalgesia (ED50 = 11-40 mpk). Several orally active diarylimidazoles show no GI toxicity in the rat and mouse up to 200 mpk.

  DOI：

  10.1021/jm9700225

文献信息

• Efficient and highly regioselective direct C-2 arylation of azoles, including free (NH)-imidazole, -benzimidazole and -indole, with aryl halides
  作者：Fabio Bellina、Chiara Calandri、Silvia Cauteruccio、Renzo Rossi

  DOI：10.1016/j.tet.2006.12.068

  日期：2007.2

  -indole, with aryl iodides under ligandless and base-free conditions provides regioselectively the required 2-arylheterocycle derivatives in high yields. 2-Aryl-1-phenyl-1H-imidazoles can also be prepared by a one-pot domino HALEX and Pd- and Cu-mediated arylation reactions of 1-phenyl-1H-imidazole with activated and unactivated aryl bromides under base-free and ligandless conditions. The protocol

  在无配体和无碱条件下，各种π电子足够的杂芳烃（包括游离的（NH）-咪唑，-苯并咪唑和-吲哚）与Pd和Cu介导的反应与芳基碘化物在区域上选择性地提供了所需的2-高产率的芳基杂环衍生物。2-芳基-1-苯基-1 H-咪唑也可以通过在碱性条件下通过一锅多米诺骨牌HALEX以及Pd和Cu介导的1-苯基-1 H-咪唑与活化和未活化的芳基溴化物的芳基化反应来制备自由和无配体的条件。已经发现涉及使用芳基碘化物的2-芳基唑的合成方案适用于有效制备三种生物活性化合物和乙酰肝素酶抑制剂合成中的关键中间体。
• Regiocontrolled Synthesis of 1,2-Diaryl-1H-imidazoles by Palladium- and Copper-Mediated Direct Coupling of 1-Aryl-1H-imidazoles with Aryl Halides under Ligandless Conditions
  作者：Fabio Bellina、Silvia Cauteruccio、Luisa Mannina、Renzo Rossi、Stéphane Viel

  DOI：10.1002/ejoc.200500636

  日期：2006.2

  involving the formation of an organocopper(I) derivatives followed by a transmetallation reaction with an arylpalladium(II) halide species and a reductive elimination, is proposed. New one-step procedures for the synthesis of 1,2,5-triaryl-1H-imidazoles, based on palladium- and copper-mediated arylation of 1-aryl-1H-imidazoles, have also been developed. Interestingly, some imidazole derivatives prepared in

  通过在 DMF 中将 1-芳基-1H-咪唑与芳基碘化物或溴化物直接偶联，以中等至高产率区域选择性地合成了多种 1,2-二芳基-1H-咪唑，包括选择性 COX-2 抑制剂。在无配体条件下存在 CsF 和催化量的 Pd(OAc)2。提出了这种新的高区域选择性 C-2 芳基化反应的可能机制，包括形成有机铜 (I) 衍生物，然后与芳基钯 (II) 卤化物物种进行金属转移反应和还原消除。还开发了基于钯和铜介导的 1-芳基-1H-咪唑芳基化的新一步法合成 1,2,5-三芳基-1H-咪唑。有趣的是，已发现本研究中制备的某些咪唑衍生物对某些人类肿瘤细胞系具有显着的细胞毒活性。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2006)
• Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
  申请人：Pharmacia Corporation

  公开号：US20040220187A1

  公开（公告）日：2004-11-04

  The present invention provides compositions and methods for the treatment of pain, inflammation or inflammation-mediated disorders in a subject. More particularly, the invention provides a combination therapy for the treatment of pain, inflammation or inflammation mediated disorders comprising the administration to a subject of a sodium ion channel blocker in combination with a cyclooxygenase-2 selective inhibitor.

  本发明提供了用于治疗疼痛、炎症或炎症介导性疾病的组合物和方法。更具体地，本发明提供了一种联合疗法，用于治疗疼痛、炎症或炎症介导性疾病，包括向受试者施用钠离子通道阻滞剂与环氧合酶-2选择性抑制剂的组合。
• Pd-Catalyzed N-arylation of 2-imidazolines Provides Convenient Access to Selective Cyclooxygenase-2 Inhibitors
  作者：Mikhail Krasavin

  DOI：10.2174/1570178611310040002

  日期：2013.5.1

  The re-emergence, in the recent years, of cyclooxygenase as a biological target in therapeutic areas other than inflammation is likely to require new optimized leads, particularly suited for the requirements of specific drug development programs. We developed a convenient synthesis of the known imidazole-based selective COX-2 inhibitors bearing primary sulphonamide and methyl sulfone substituents, via Pd-catalyzed imidazoline N-arylation as a key step, followed by dehydrogenation.

  近年来，环氧化酶作为生物靶点重新出现在炎症以外的治疗领域，这可能需要新的优化线索，特别是适合特定药物开发计划要求的线索。我们开发了一种简便的合成方法，通过钯催化咪唑啉 N-芳基化作为关键步骤，然后进行脱氢反应，合成出含有初级磺酰胺和甲基砜取代基的已知咪唑类选择性 COX-2 抑制剂。
• Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia
  申请人：Masferrer L. Jaime

  公开号：US20050187172A1

  公开（公告）日：2005-08-25

  The present invention provides combinations of a Cox-2 inhibitor and a DNA topoisomerase inhibitor and methods of use thereof for preventing and/or treating neoplasia or or a neoplasia-related disorder in a subject.

  本发明提供了一种COX-2抑制剂和DNA拓扑异构酶抑制剂的组合物，以及它们的使用方法，用于预防和/或治疗受试者中的肿瘤或与肿瘤相关的疾病。